Precision medicine based on genomic profiling and its success in certain medical fields such as oncology is promising. Since diagnostic decisions in intensive care settings are complex and require decision-making that integrates diverse data in real time, conventional sequencing technologies are not suitable. Fast sequencing technology can generate genetic and transcriptional data in a few hours. It has been suggested that these real-time technologies could transform the management of critical patients. The goal of the project is to determine the clinical validity of gene activity profiles and to identify patterns that predict the risk of complications in critically ill patients. The researchers will evaluate the implementation of an integrative, realtime, bedside approach,of molecular characterization combined with models developed from clinical data and will evaluate the generalization of the models developed. Ultimately, it is hoped that the direct impact of this innovative project will be a more rapid and targeted intervention in situations where decision-making is difficult and complex. Benefits could also include a reduction and more thoughtful use of antimicrobial interventions, optimization in the use of analgesic and sedative drugs (and thus reduce the duration of mechanical ventilation and its associated complications) and potentially a reduction in the costs associated with complications.
The amount invested by Génome Québec for this project is $250,000. In addition, IVADO has already invested $1.2M in this project. This project is part of the IVADO strategic funding program : Human health and secondary use of data
Lead Genome Centre: Génome Québec
Partner: IVADO